Logo

CNSP

CNS Pharmaceuticals, Inc.

CNSP

CNS Pharmaceuticals, Inc. • NASDAQ
$7.24 ▲ 7.42% (+0.50)
Market Cap $4.16 M
52w High $114.00
52w Low $4.93
Dividend Yield 0%
P/E 0.01
Volume 1.99K
Outstanding Shares 574.58K

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $3.253M ▲ $-3.218M ▼ 0% $-104.35 ▼ $-3.216M ▼
Q2-2025 $0 $2.408M ▼ $-2.375M ▲ 0% $-77.04 ▼ $-2.37M ▲
Q1-2025 $0 $4.337M ▲ $-4.301M ▼ 0% $-18.96 ▼ $-4.294M ▼
Q4-2024 $0 $3.199M ▼ $-3.176M ▲ 0% $-2.96 ▲ $-3.173M ▲
Q3-2024 $0 $5.628M $-5.606M 0% $-3 $-5.603M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $9.864M ▼ $11.869M ▼ $1.959M ▲ $9.91M ▼
Q2-2025 $12.13M ▼ $14.508M ▲ $1.383M ▼ $13.125M ▲
Q1-2025 $13.048M ▲ $13.749M ▲ $2.779M ▲ $10.97M ▲
Q4-2024 $6.461M ▼ $8.701M ▲ $2.524M ▼ $6.177M ▲
Q3-2024 $6.973M $7.409M $4.057M $3.352M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-3.218M ▼ $-2.174M ▲ $0 $-91.616K ▼ $-2.266M ▼ $-2.174M ▲
Q2-2025 $-2.375M ▲ $-5.343M ▼ $0 $4.426M ▼ $-917.719K ▼ $-5.343M ▼
Q1-2025 $-4.301M ▼ $-3.242M ▲ $0 ▲ $9.828M ▲ $6.586M ▲ $-3.242M ▲
Q4-2024 $-3.176M ▲ $-5.471M ▲ $-4.188K ▼ $4.963M ▼ $-511.746K ▼ $-5.475M ▲
Q3-2024 $-5.606M $-6.8M $0 $12.282M $5.482M $-6.8M

Five-Year Company Overview

Income Statement

Income Statement CNS Pharmaceuticals is still a pure development-stage biotech: it has essentially no product revenue and has reported consistent operating and net losses over the past several years. Its costs are mainly tied to research, trials, and overhead, and those expenses are not yet being offset by any commercial sales. Losses have been persistent and meaningful in relation to the company’s very small size, reflecting the typical “cash burn” pattern of early-stage biotechnology firms that are funding clinical programs long before any potential approvals or revenues.

Balance Sheet

Balance Sheet The balance sheet is very thin, with only a modest base of assets and cash and no reported debt. Equity has stayed positive but small, which, combined with repeated reverse stock splits, suggests the company has relied heavily on issuing new shares over time to fund operations. The lack of debt reduces financial leverage risk, but the limited asset base and small cash cushion highlight an ongoing dependence on external financing to sustain the business and its clinical programs.

Cash Flow

Cash Flow Cash flow reflects the company’s development-stage status: money is consistently flowing out to cover operations, with no meaningful cash coming in from product sales. Operating and free cash flow have been steadily negative, and capital spending is minimal, so nearly all cash usage is tied to running the company and advancing the pipeline. This pattern indicates that CNS Pharmaceuticals will likely need periodic capital raises or partnerships to keep funding trials unless its cash position is strengthened.

Competitive Edge

Competitive Edge CNS Pharmaceuticals is narrowly focused on aggressive brain cancers, especially glioblastoma, where treatment options are limited and outcomes are poor. Its main strength is a technology and drug portfolio designed to cross the blood–brain barrier, a major obstacle for many cancer drugs. Orphan Drug Designation for its lead candidates offers potential regulatory and commercial advantages, including exclusivity periods if approved. However, the company is small, has no marketed products, and operates in a space crowded with larger players and other experimental approaches, which makes its position promising but still highly uncertain and dependent on clinical success.

Innovation and R&D

Innovation and R&D The company’s innovation story centers on Berubicin and TPI-287, two drug candidates specifically engineered to reach tumors in the brain. Being able to cross the blood–brain barrier is a genuine scientific edge if it translates into clear patient benefit. Early-stage trial results and regulatory designations are encouraging, and management has shown a willingness to expand the pipeline through licensing. That said, both key assets remain in clinical development, and significant scientific, regulatory, and execution risks remain before any of this innovation can turn into sustainable commercial value.

Summary

CNS Pharmaceuticals is a highly early-stage, high-risk biotech focused on a difficult but important medical problem: aggressive brain cancers. Financially, it has no revenue, ongoing losses, and steady cash burn, supported mainly by equity financing rather than debt. Its scientific proposition—brain-penetrant cancer drugs with orphan designations—is differentiated and potentially valuable if late-stage trials succeed. At the same time, the tiny balance sheet, repeated reverse stock splits, reliance on new funding, and all-or-nothing dependence on a small number of clinical assets mean outcomes could vary widely, from significant upside if trials and approvals go well to material downside if they do not.

NEWS

November 17, 2025 · 8:35 AM UTC

CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Read more

November 10, 2025 · 8:45 AM UTC

CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting

Read more

September 3, 2025 · 9:15 AM UTC

CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Read more